Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA counterfeit bulk drug information requested by House Commerce Committee.

This article was originally published in The Tan Sheet

Executive Summary

FDA COUNTERFEIT BULK DRUG INFO REQUESTED BY HOUSE COMMERCE CMTE. Chairman Thomas Bliley (R-Va.) and Oversight Subcommittee Chairman Joe Barton (R-Tex.) in the form of complete records of agency meetings and actions on the subject in anticipation of hearings on the agency's foreign inspection program. An Aug. 4 letter requests a list of "all FDA enforcement actions and/or investigations" involving counterfeit bulk drug substances since Jan. 1, 1990. The committee also wants copies of all internal FDA records relating to counterfeit bulk drugs during the same period.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel